Vanguard Group
MCRB icon

Vanguard Group’s Seres Therapeutics MCRB Stock Holding History

Vanguard Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$4.82M Buy
324,214
+12,325
+4% +$215K ﹤0.01% 3266
2025
Q3 		$6M Buy
311,889
+19,793
+7% +$316K ﹤0.01% 3211
2025
Q2 		$3.25M Sell
292,096
-12,504
-4% -$110K ﹤0.01% 3360
2025
Q1 		$4.26M Buy
304,600
+10,906
+4% +$171K ﹤0.01% 3235
2024
Q4 		$4.88M Sell
293,694
-9,332
-3% -$152K ﹤0.01% 3282
2024
Q3 		$5.73M Sell
303,026
-11,261
-4% -$228K ﹤0.01% 3220
2024
Q2 		$4.55M Sell
314,287
-22,454
-7% -$375K ﹤0.01% 3299
2024
Q1 		$5.21M Buy
336,741
+36,476
+12% +$787K ﹤0.01% 3287
2023
Q4 		$8.41M Buy
300,265
+26,428
+10% +$694K ﹤0.01% 3050
2023
Q3 		$13M Buy
273,837
+5,978
+2% +$456K ﹤0.01% 2725
2023
Q2 		$25.7M Sell
267,859
-24,798
-8% -$2.7M ﹤0.01% 2486
2023
Q1 		$33.2M Sell
292,657
-11,990
-4% -$1.3M ﹤0.01% 2367
2022
Q4 		$34.1M Sell
304,647
-25,896
-8% -$3.47M ﹤0.01% 2360
2022
Q3 		$42.4M Buy
330,543
+64,002
+24% +$6.55M ﹤0.01% 2266
2022
Q2 		$18.3M Buy
266,541
+13,194
+5% +$1.14M ﹤0.01% 2681
2022
Q1 		$36.1M Buy
253,347
+19,534
+8% +$3M ﹤0.01% 2464
2021
Q4 		$39M Buy
233,813
+35,999
+18% +$5.72M ﹤0.01% 2489
2021
Q3 		$27.5M Buy
197,814
+27,535
+16% +$5.39M ﹤0.01% 2674
2021
Q2 		$81.2M Sell
170,279
-685
-0.4% -$289K ﹤0.01% 2109
2021
Q1 		$70.4M Buy
170,964
+12,598
+8% +$5.8M ﹤0.01% 2129
2020
Q4 		$77.6M Buy
158,366
+20,599
+15% +$12.1M ﹤0.01% 1962
2020
Q3 		$78M Buy
137,767
+24,868
+22% +$8.27M ﹤0.01% 1805
2020
Q2 		$10.7M Buy
112,899
+5,141
+5% +$451K ﹤0.01% 2734
2020
Q1 		$7.69M Buy
107,758
+776
+0.7% +$52K ﹤0.01% 2739
2019
Q4 		$7.38M Buy
106,982
+2,368
+2% +$176K ﹤0.01% 2998
2019
Q3 		$8.39M Buy
104,614
+1,598
+2% +$106K ﹤0.01% 2907
2019
Q2 		$6.63M Buy
103,016
+57,964
+129% +$5.5M ﹤0.01% 3069
2019
Q1 		$6.19M Buy
45,052
+2,510
+6% +$306K ﹤0.01% 3059
2018
Q4 		$3.85M Sell
42,542
-8,940
-17% -$1.25M ﹤0.01% 3169
2018
Q3 		$7.82M Sell
51,482
-19,331
-27% -$3.13M ﹤0.01% 3043
2018
Q2 		$12.2M Sell
70,813
-14,990
-17% -$2.45M ﹤0.01% 2805
2018
Q1 		$12.6M Buy
85,803
+8,075
+10% +$1.55M ﹤0.01% 2709
2017
Q4 		$15.8M Sell
77,728
-5,441
-7% -$1.12M ﹤0.01% 2600
2017
Q3 		$26.7M Buy
83,169
+3,918
+5% +$1.07M ﹤0.01% 2356
2017
Q2 		$17.9M Buy
79,251
+968
+1% +$199K ﹤0.01% 2505
2017
Q1 		$17.6M Buy
78,283
+5,173
+7% +$1.05M ﹤0.01% 2489
2016
Q4 		$14.5M Buy
73,110
+5,750
+9% +$1.25M ﹤0.01% 2569
2016
Q3 		$16.6M Buy
67,360
+8,514
+14% +$2.99M ﹤0.01% 2440
2016
Q2 		$34.2M Buy
58,846
+11,498
+24% +$6.75M ﹤0.01% 2074
2016
Q1 		$25.2M Buy
47,348
+20,110
+74% +$10.5M ﹤0.01% 2187
2015
Q4 		$19.1M Buy
27,238
+3,230
+13% +$2.12M ﹤0.01% 2323
2015
Q3 		$14.2M Buy
24,008
+23,008
+2,301% +$18.8M ﹤0.01% 2433
2015
Q2 		$830K Buy
+1,000
New +$873K ﹤0.01% 3714

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group's MCRB Position: Q4 2025 in Review

Vanguard Group increased its Seres Therapeutics (MCRB) stake by 4% in Q4 2025, buying an estimated $215K and bringing the position to 324,214 shares worth $4.82M. The position accounts for ﹤0.01% of the portfolio, ranked #3266.

Vanguard Group first reported a position in MCRB in Q2 2015 and has held it in 43 quarters since. The position peaked at $81.2M in Q2 2021. 36 funds tracked by Wall St. Rank hold MCRB as of Q4 2025.

  • Vanguard Group held 324,214 shares of Seres Therapeutics worth $4.82M as of Q4 2025.
  • Vanguard Group bought 12,325 Seres Therapeutics shares in Q4 2025, an estimated $215K.
  • Seres Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3266 holding.
  • Vanguard Group first reported a position in Seres Therapeutics in Q2 2015 and has held it in 43 quarters since.
  • Vanguard Group's Seres Therapeutics position peaked at $81.2M in Q2 2021.
  • 36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.